Observational study of dronedarone in Taiwanese patients with atrial fibrillation

Jiunn-Lee Lin, Tsu Juey Wu, Ching Pei Chen, Jung Cheng Hsu, Kwo Chang Ueng, Jen Yuan Kuo, Mien Cheng Chen, Kuan Hung Yeh, Kuan Cheng Chang, Yen Yu Lu, Kou Gi Shyu, Ming Shien Wen, Shih Ann Chen, Ming Hsiung Hsieh, Wei Kung Tseng, An Ning Feng, Teng Yao Yang, Wen Chin Ko, Chi Wen Cheng, Ju Chi LiuWen Ter Lai

Research output: Contribution to journalArticle

Abstract

Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 ± 7.2 years), 95.2% had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1% at baseline vs. 67.4% at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 ± 16.2 vs. 74.0 ± 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5% of patients reported treatment-related AEs. However, only 0.2% of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type.

Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Atrial Fibrillation
Observational Studies
Therapeutics
Safety
Anti-Arrhythmia Agents
dronedarone
Statistical Factor Analysis
Quality of Life
Population

Keywords

  • Atrial fibrillation
  • Dronedarone
  • Observational
  • Quality of life
  • Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Observational study of dronedarone in Taiwanese patients with atrial fibrillation. / Lin, Jiunn-Lee; Wu, Tsu Juey; Chen, Ching Pei; Hsu, Jung Cheng; Ueng, Kwo Chang; Kuo, Jen Yuan; Chen, Mien Cheng; Yeh, Kuan Hung; Chang, Kuan Cheng; Lu, Yen Yu; Shyu, Kou Gi; Wen, Ming Shien; Chen, Shih Ann; Hsieh, Ming Hsiung; Tseng, Wei Kung; Feng, An Ning; Yang, Teng Yao; Ko, Wen Chin; Cheng, Chi Wen; Liu, Ju Chi; Lai, Wen Ter.

In: Journal of the Formosan Medical Association, 01.01.2019.

Research output: Contribution to journalArticle

Lin, J-L, Wu, TJ, Chen, CP, Hsu, JC, Ueng, KC, Kuo, JY, Chen, MC, Yeh, KH, Chang, KC, Lu, YY, Shyu, KG, Wen, MS, Chen, SA, Hsieh, MH, Tseng, WK, Feng, AN, Yang, TY, Ko, WC, Cheng, CW, Liu, JC & Lai, WT 2019, 'Observational study of dronedarone in Taiwanese patients with atrial fibrillation', Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2019.03.009
Lin, Jiunn-Lee ; Wu, Tsu Juey ; Chen, Ching Pei ; Hsu, Jung Cheng ; Ueng, Kwo Chang ; Kuo, Jen Yuan ; Chen, Mien Cheng ; Yeh, Kuan Hung ; Chang, Kuan Cheng ; Lu, Yen Yu ; Shyu, Kou Gi ; Wen, Ming Shien ; Chen, Shih Ann ; Hsieh, Ming Hsiung ; Tseng, Wei Kung ; Feng, An Ning ; Yang, Teng Yao ; Ko, Wen Chin ; Cheng, Chi Wen ; Liu, Ju Chi ; Lai, Wen Ter. / Observational study of dronedarone in Taiwanese patients with atrial fibrillation. In: Journal of the Formosan Medical Association. 2019.
@article{c579e6831d784e4aa967f053b0b3e50c,
title = "Observational study of dronedarone in Taiwanese patients with atrial fibrillation",
abstract = "Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 ± 7.2 years), 95.2{\%} had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1{\%} at baseline vs. 67.4{\%} at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 ± 16.2 vs. 74.0 ± 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5{\%} of patients reported treatment-related AEs. However, only 0.2{\%} of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type.",
keywords = "Atrial fibrillation, Dronedarone, Observational, Quality of life, Safety",
author = "Jiunn-Lee Lin and Wu, {Tsu Juey} and Chen, {Ching Pei} and Hsu, {Jung Cheng} and Ueng, {Kwo Chang} and Kuo, {Jen Yuan} and Chen, {Mien Cheng} and Yeh, {Kuan Hung} and Chang, {Kuan Cheng} and Lu, {Yen Yu} and Shyu, {Kou Gi} and Wen, {Ming Shien} and Chen, {Shih Ann} and Hsieh, {Ming Hsiung} and Tseng, {Wei Kung} and Feng, {An Ning} and Yang, {Teng Yao} and Ko, {Wen Chin} and Cheng, {Chi Wen} and Liu, {Ju Chi} and Lai, {Wen Ter}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2019.03.009",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - Observational study of dronedarone in Taiwanese patients with atrial fibrillation

AU - Lin, Jiunn-Lee

AU - Wu, Tsu Juey

AU - Chen, Ching Pei

AU - Hsu, Jung Cheng

AU - Ueng, Kwo Chang

AU - Kuo, Jen Yuan

AU - Chen, Mien Cheng

AU - Yeh, Kuan Hung

AU - Chang, Kuan Cheng

AU - Lu, Yen Yu

AU - Shyu, Kou Gi

AU - Wen, Ming Shien

AU - Chen, Shih Ann

AU - Hsieh, Ming Hsiung

AU - Tseng, Wei Kung

AU - Feng, An Ning

AU - Yang, Teng Yao

AU - Ko, Wen Chin

AU - Cheng, Chi Wen

AU - Liu, Ju Chi

AU - Lai, Wen Ter

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 ± 7.2 years), 95.2% had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1% at baseline vs. 67.4% at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 ± 16.2 vs. 74.0 ± 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5% of patients reported treatment-related AEs. However, only 0.2% of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type.

AB - Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 ± 7.2 years), 95.2% had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1% at baseline vs. 67.4% at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 ± 16.2 vs. 74.0 ± 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5% of patients reported treatment-related AEs. However, only 0.2% of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type.

KW - Atrial fibrillation

KW - Dronedarone

KW - Observational

KW - Quality of life

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85064516545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064516545&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2019.03.009

DO - 10.1016/j.jfma.2019.03.009

M3 - Article

AN - SCOPUS:85064516545

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -